RxDoctor Payments Data

Arielle Holliday, PA

Medical · Fairfax, VANPI 1396399671

Payments from drug & device makers

$1,142in general payments, 2019–2025

Across 34 payments — averaging $33.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$380
  • Inari Medical, Inc.$205
  • GSK$137
  • Jazz Pharmaceuticals Inc.$126
  • Harmony Biosciences LLC$88
  • Vifor Pharma, Inc.$72
  • plus $134 from 4 others

What the payments were for

  • Food & beverage$1,142100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,142 in reported general payments places this provider in the 60th percentile of 632 medical providers in Virginia.

See all medical providers in Virginia

Medicare billing

Part B allowed, 2024
$68,837
Medicare patients
168
Services billed
1,224

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter126$127,146
Breztri AerosphereBudesonide/Glycopyr/Formoterol47$44,537
Dupixent PenDupilumab11$38,998
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr51$31,929
SymbicortBudesonide/Formoterol Fumarate81$27,967
Spiriva RespimatTiotropium Bromide24$26,220
Breo ElliptaFluticasone/Vilanterol44$21,363
Combivent RespimatIpratropium/Albuterol Sulfate20$20,672
XareltoRivaroxaban17$15,232
Spiriva HandihalerTiotropium Bromide16$14,462
Incruse ElliptaUmeclidinium Bromide21$11,147
Advair HfaFluticasone Propion/Salmeterol25$9,820
Stiolto RespimatTiotropium Br/Olodaterol Hcl16$8,661
DuleraMometasone/Formoterol13$7,025
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate21$5,020

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta$137$191,586242 claims
AstraZenecaBreztri Aerosphere, Symbicort$380$72,504128 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 632 medical providers in Virginia.

Other medical in Fairfax

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →